Urology and China weigh on near-term expectations
17/06/25 -"We have cut our FY2025 EPS estimates to factor in: 1. A softer than expected showing in China, as reflected in the H1 2025 performance 2. Ongoing challenges in Urology, which have been exacerbated by ..."
Pages
63
Language
English
Published on
17/06/25
You may also be interested by these reports :
06/02/26
Coloplast delivered a weak Q1, with both revenue and adjusted EBIT missing consensus. Organic growth of 6% was in line with expectations, but ...
06/02/26
Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with ...
05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...
05/02/26
Our estimates have been moderated following the Q4 25 miss, primarily reflecting a softer order book and growth momentum (especially for the LS ...